293 related articles for article (PubMed ID: 29911750)
1. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
Mahmoud LB; Mdhaffar M; Frikha R; Ghozzi H; Hakim A; Sahnoun Z; Elloumi M; Zeghal K
Adv Clin Exp Med; 2018 Aug; 27(8):1061-1068. PubMed ID: 29911750
[TBL] [Abstract][Full Text] [Related]
2. Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma.
Kantar M; Kosova B; Cetingul N; Gumus S; Toroslu E; Zafer N; Topcuoglu N; Aksoylar S; Cinar M; Tetik A; Eroglu Z
Leuk Lymphoma; 2009 Jun; 50(6):912-7. PubMed ID: 19391036
[TBL] [Abstract][Full Text] [Related]
3. Study of the pharmacokinetic and pharmacogenetic contribution to the toxicity of high-dose methotrexate in children with acute lymphoblastic leukemia.
El-Khodary NM; El-Haggar SM; Eid MA; Ebeid EN
Med Oncol; 2012 Sep; 29(3):2053-62. PubMed ID: 21644011
[TBL] [Abstract][Full Text] [Related]
4. Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma.
Faganel Kotnik B; Grabnar I; Bohanec Grabar P; Dolžan V; Jazbec J
Eur J Clin Pharmacol; 2011 Oct; 67(10):993-1006. PubMed ID: 21509569
[TBL] [Abstract][Full Text] [Related]
5. [Relationship between the methylenetetrahydrofolate reductase gene polymorphism and adverse reactions of high-dose methotrexate in children with acute lymphocytic leukemia].
Zheng MM; Yue LJ; Chen XW; Wen FQ; Li CG; Yang CL; Xie C; Ding H
Zhongguo Dang Dai Er Ke Za Zhi; 2013 Mar; 15(3):201-6. PubMed ID: 23498762
[TBL] [Abstract][Full Text] [Related]
6. Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies.
Suthandiram S; Gan GG; Zain SM; Bee PC; Lian LH; Chang KM; Ong TC; Mohamed Z
Pharmacogenomics; 2014 Aug; 15(11):1479-94. PubMed ID: 25303299
[TBL] [Abstract][Full Text] [Related]
7. Impact of methylenetetrahydrofolate reductase (MTHFR) polymorphisms on methotrexate-induced toxicities in acute lymphoblastic leukemia: a meta-analysis.
Yang L; Hu X; Xu L
Tumour Biol; 2012 Oct; 33(5):1445-54. PubMed ID: 22528943
[TBL] [Abstract][Full Text] [Related]
8. Influence of pre-hydration and pharmacogenetics on plasma methotrexate concentration and renal dysfunction following high-dose methotrexate therapy.
Yanagimachi M; Goto H; Kaneko T; Naruto T; Sasaki K; Takeuchi M; Tanoshima R; Kato H; Yokosuka T; Kajiwara R; Fujii H; Tanaka F; Goto S; Takahashi H; Mori M; Kai S; Yokota S
Int J Hematol; 2013 Dec; 98(6):702-7. PubMed ID: 24241962
[TBL] [Abstract][Full Text] [Related]
9. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia.
Lopez-Lopez E; Martin-Guerrero I; Ballesteros J; Piñan MA; Garcia-Miguel P; Navajas A; Garcia-Orad A
Pediatr Blood Cancer; 2011 Oct; 57(4):612-9. PubMed ID: 21387541
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia.
Salazar J; Altés A; del Río E; Estella J; Rives S; Tasso M; Navajas A; Molina J; Villa M; Vivanco JL; Torrent M; Baiget M; Badell I
Pharmacogenomics J; 2012 Oct; 12(5):379-85. PubMed ID: 21747412
[TBL] [Abstract][Full Text] [Related]
12. Functional variants of gene encoding folate metabolizing enzyme and methotrexate-related toxicity in children with acute lymphoblastic leukemia.
Kałużna E; Strauss E; Zając-Spychała O; Gowin E; Świątek-Kościelna B; Nowak J; Fichna M; Mańkowski P; Januszkiewicz-Lewandowska D
Eur J Pharmacol; 2015 Dec; 769():93-9. PubMed ID: 26528799
[TBL] [Abstract][Full Text] [Related]
13. The effects of genetic polymorphism on toxicity and pharmacokinetics of methotrexate in Egyptian adult patients with leukaemia or lymphoma.
Shendy K; Abdelkawy K; Ali AA; Belal F; Abdelhakiem M; Magdy G; Anber N; Elbarbry F
Xenobiotica; 2024 Feb; 54(2):95-105. PubMed ID: 38381003
[TBL] [Abstract][Full Text] [Related]
14. Effects of methylenetetrahydrofolate reductase gene polymorphisms on toxicities during consolidation therapy in pediatric acute lymphoblastic leukemia in a Chinese population.
Liu SG; Li ZG; Cui L; Gao C; Li WJ; Zhao XX
Leuk Lymphoma; 2011 Jun; 52(6):1030-40. PubMed ID: 21534867
[TBL] [Abstract][Full Text] [Related]
15. C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase gene: effect on methotrexate-related toxicity in adult acute lymphoblastic leukaemia.
Eissa DS; Ahmed TM
Blood Coagul Fibrinolysis; 2013 Mar; 24(2):181-8. PubMed ID: 23183238
[TBL] [Abstract][Full Text] [Related]
16. MTHFR 677 (C-->T) polymorphism is not relevant for prognosis or therapy-associated toxicity in pediatric NHL: results from 484 patients of multicenter trial NHL-BFM 95.
Seidemann K; Book M; Zimmermann M; Meyer U; Welte K; Stanulla M; Reiter A
Ann Hematol; 2006 May; 85(5):291-300. PubMed ID: 16463153
[TBL] [Abstract][Full Text] [Related]
17. Methotrexate-induced mucositis in acute leukemia patients is not associated with the MTHFR 677T allele in Mexico.
Ruiz-Argüelles GJ; Coconi-Linares LN; Garcés-Eisele J; Reyes-Núñez V
Hematology; 2007 Oct; 12(5):387-91. PubMed ID: 17891601
[TBL] [Abstract][Full Text] [Related]
18. Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia.
Csordas K; Lautner-Csorba O; Semsei AF; Harnos A; Hegyi M; Erdelyi DJ; Eipel OT; Szalai C; Kovacs GT
Br J Haematol; 2014 Aug; 166(3):410-20. PubMed ID: 24712521
[TBL] [Abstract][Full Text] [Related]
19. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia.
Radtke S; Zolk O; Renner B; Paulides M; Zimmermann M; Möricke A; Stanulla M; Schrappe M; Langer T
Blood; 2013 Jun; 121(26):5145-53. PubMed ID: 23652803
[TBL] [Abstract][Full Text] [Related]
20. High dose methotrexate treatment in childhood ALL: pilot study on the impact of the MTHFR 677C>T and 1298A>C polymorphisms on MTX-related toxicity.
Haase R; Elsner K; Merkel N; Stiefel M; Mauz-Körholz C; Kramm CM; Körholz D
Klin Padiatr; 2012 Apr; 224(3):156-9. PubMed ID: 22513795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]